

[54] OXAZINONE COMPOUNDS FOR THE PREPARATION OF TAXOL

[75] Inventor: Robert A. Holton, Tallahassee, Fla.

[73] Assignee: Florida State University, Tallahassee, Fla.

[21] Appl. No.: 898,438

[22] Filed: Jun. 15, 1992

Related U.S. Application Data

[60] Division of Ser. No. 603,041, Oct. 30, 1990, Pat. No. 5,136,060, which is a continuation-in-part of Ser. No. 436,235, Nov. 14, 1989, Pat. No. 5,015,744.

[51] Int. Cl.⁶ C07D 305/00; C07D 413/12

[52] U.S. Cl. 544/97; 549/510; 549/511; 549/512; 549/513; 560/30; 560/45; 564/183

[58] Field of Search 544/97; 549/510, 511

[56] References Cited

U.S. PATENT DOCUMENTS

4,521,599 6/1985 Skulnick et al. 544/97
4,814,470 3/1989 Colin et al. 514/449
4,857,653 8/1989 Colin et al. 549/511
4,876,399 10/1989 Holton et al. 549/510
4,924,011 5/1990 Denis et al. 549/510
4,924,012 5/1990 Colin et al. 549/510
4,960,790 10/1990 Stella et al. 549/510

FOREIGN PATENT DOCUMENTS

30606/89 2/1989 Australia .
253738 7/1987 European Pat. Off. .
253739 7/1987 European Pat. Off. .
336840 4/1989 European Pat. Off. .
336841 4/1989 European Pat. Off. .
7639 8/1989 WIPO .

OTHER PUBLICATIONS

W. Steglich et al., "1,3-oxazin-6-ones: Versatile Intermediates in Heterocyclic Syntheses", *Gazz. Chim. Ital.*, vol. 116, No. 7, 1986, pp. 361-372.

V. E. Zakhs et al., "Oxo Derivatives of 1,3-Oxazines",

Chem. of Heterocyclic Compounds, vol. 11, 1987, pp. 1147-1166.

Dennis et al., "A Highly Efficient, Practical Approach to Natural Taxol", *J. Am. Chem. Soc.* 1988, 110, 5917-5919.

Holton et al., "A Synthesis of Taxusin", *J. Am. Chem. Soc.*, 1988, 110, pp. 6558-6560.

Holton, "Synthesis of the Taxane Ring System", *J. Am. Chem. Soc.*, 1984, 106, pp. 5731-5732.

Katritzky, "Handbook of Heterocyclic Chemistry", Pergamon Press, p. 173.

March, *Advanced Org. Chem.* 3rd Ed., p. 351, Reaction 0-25, Alcoholysis of Esters.


Wani et al., "Plant Antitumor Agents, VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from *Taxus Brevifolia*", *J. Am. Chem. Soc.* 93:9, May 5, 1971, pp. 2325-2327.

Primary Examiner—Cecilia Tsang

Attorney, Agent, or Firm—Senniger, Powers, Leavitt & Roedel

[57] ABSTRACT

Process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone having the formula:



1

wherein R₁ is aryl, heteroaryl, alkyl, alkenyl, alkynyl or OR₇ wherein R₇ is alkyl, alkenyl, alkynyl, aryl or heteroaryl; R₂ and R₅ are independently selected from hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl, and OR₈ wherein R₈ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxyl protecting group; and R₃ and R₆ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and heteroaryl.

26 Claims, No Drawings

OXAZINONE COMPOUNDS FOR THE PREPARATION OF TAXOL

This invention was made with government support under NIH Grant CA 42031 awarded by the National Institute of Health. The government has certain rights in the invention.


CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of copending application Ser. No. 07/603,041, filed Oct. 30, 1990, now U.S. Pat. No. 5,136,060 which is a continuation-in-part of copending application Ser. No. 07/436,235, filed Nov. 14, 1989, now U.S. Pat. No. 5,015,744.

BACKGROUND OF THE INVENTION

The present invention is directed to a novel oxazinone, a process for its preparation, and a process for the preparation of taxol involving the use of such oxazinone.

The taxane family of terpenes, of which taxol is a member, has attracted considerable interest in both the biological and chemical arts. Taxol is a promising cancer chemotherapeutic agent with a broad spectrum of antileukemic and tumor-inhibiting activity, having the following structure:




Because of this promising activity, taxol is currently undergoing clinical trials in both France and the United States.

The supply of taxol for these clinical trials is presently being provided by the bark from several species of yew. However, taxol is found only in minute quantities in the bark of these slow growing evergreens, causing considerable concern that the limited supply of taxol will not meet the demand. Consequently, chemists in recent years have expended their energies in trying to find a viable synthetic route for the preparation of taxols. So far, the results have not been entirely satisfactory.

One synthetic route that has been proposed is directed to the synthesis of the tetracyclic taxane nucleus from commodity chemicals. A synthesis of the taxol congener taxusin has been reported by Holton, et al. in JACS 110, 6558 (1988). Despite the progress made in this approach, the final total synthesis of taxol is, nevertheless, likely to be a multi-step, tedious, and costly process.

An alternate approach to the preparation of taxol has been described by Greene, et al. in JACS 110, 5917 (1988), and involves the use of a congener of taxol, 10-deacetyl baccatin III which has the structure shown below:




10-deacetyl baccatin III is more readily available than taxol since it can be obtained from the leaves of *Taxus baccata*. According to the method of Greene et al., 10-deacetyl baccatin III is converted to taxol by attachment of the C10 acetyl group and by attachment of the C13 β -amido ester side chain through the esterification of the C13 alcohol with a β -amido carboxylic acid unit. Although this approach requires relatively few steps, the synthesis of the β -amido carboxylic acid unit is a multi-step process which proceeds in low yield, and the coupling reaction is tedious and also proceeds in low yield. However, this coupling reaction is a key step which is required in every contemplated synthesis of taxol or biologically active derivative of taxol, since it has been shown by Wani, et al. in JACS 93, 2325 (1971) that the presence of the β -amido ester side chain at C13 is required for anti-tumor activity.

A major difficulty remaining in the synthesis of taxol and other potential anti-tumor agents is the lack of a readily available unit which could be easily attached to the C13 oxygen to provide the β -amido ester side chain. Development of such a unit and a process for its attachment in high yield would facilitate the synthesis of taxol as well as related anti-tumor agents having a modified set of nuclear substituents or a modified C13 side chain. This need has been fulfilled by the discovery of a new, readily available, side chain precursor chemical unit and an efficient process for its attachment at the C13 oxygen.

SUMMARY OF THE INVENTION

Among the objects of the present invention, therefore, is the provision of a side chain precursor for the synthesis of taxols, and the provision of a process for the attachment of the side chain precursor in relatively high yield to provide a taxol intermediate.

Briefly, therefore, the present invention is directed to a side chain precursor, an oxazinone 1 of the formula:



wherein R₁ is aryl, heteroaryl, alkyl, alkenyl, alkynyl or OR₇ wherein R₇ is alkyl, alkenyl, alkynyl, aryl or heteroaryl; R₂ and R₅ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and OR₈ wherein R₈ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxyl protecting group; and R₃ and R₆ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and heteroaryl.


The present invention is also directed to a process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone 1 in the presence of a sufficient amount of an activating agent to cause the oxazinone to react with the alcohol to form a β -amido ester which may be used as an intermediate in the synthesis of taxol.

The present invention is also directed to a process for the preparation of taxol which comprises contacting an alcohol with oxazinone 1 in the presence of a sufficient amount of an activating agent to cause the oxazinone to react with the alcohol to form a β -amido ester taxol intermediate. The intermediate is then used in the synthesis of taxol.

Other objects and features of this invention will be in part apparent and in part pointed out hereinafter.


DETAILED DESCRIPTION

The present invention is directed to an oxazinone 1 and its derivatives, the structure of which is depicted hereinbelow.




as noted above, R₁ is aryl, heteroaryl, alkyl, alkenyl, alkynyl or —OR₇ wherein R₇ is alkyl, alkenyl, alkynyl, aryl or heteroaryl; R₂ and R₅ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and —OR₈ wherein R₈ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxyl protecting group; and R₃ and R₆ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and heteroaryl.

Preferably, the oxazinone 1 has the structure




wherein R₁, R₃ and R₈ are as previously defined. Most preferably R₈ is ethoxyethyl or 2,2,2-trichloroethoxy-methyl. Thus, the structure of the most preferred oxazinone in which R₁ and R₃ are phenyl, R₅ is hydrogen and R₂ is —OR₈ being ethoxyethyl is shown below:



According to IUPAC rules, the name of oxazinone 2 is 2,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one.

In accordance with the present invention, a process is provided for preparing taxol intermediates, natural taxol and non-naturally occurring taxols having the following structural formula:



wherein

A and B are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or A and B together form an oxo;

L and D are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy;

E and F are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or; E and F together form an oxo;

G is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or

G and M together form an oxo or methylene or G and M together form an oxirane ring or M and F together form an oxetane ring;

J is hydrogen, hydroxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or

I is hydrogen, hydroxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy; or

I and J taken together form an oxo; and

K is hydrogen, hydroxy or lower alkoxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy; and

P and Q are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or P and Q together form an oxo; and

S and T are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloxyloxy or S and T together form an oxo; and

U and V are independently hydrogen or lower alkyl, alkenyl, alkynyl, aryl, or substituted aryl; and

W is aryl, substituted aryl, lower alkyl, alkenyl alkynyl, alkoxy, or aryloxy.

The taxol alkyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, aryl, hexyl, and the like.

The taxol alkenyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, aryl, hexenyl, and the like.

The taxol alkynyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, aryl, hexynyl, and the like.

5

Exemplary alkanoyloxy include acetate, propionate, butyrate, valerate, isobutyrate and the like. The more preferred alkanoyloxy is acetate.

The taxol aryl moieties, either alone or with various substituents contain from 6 to 10 carbon atoms and include phenyl, α -naphthyl or β -naphthyl. Substituents include alkanoxy, hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino, amido, etc. Phenyl is the more preferred aryl.


As defined herein, the term "aryloxy" includes any aromatic heterocyclic moieties the term "aryl" includes any compound having an aromatic ring of which no hetero atom is a member, and the term "heteroaryl" includes any compound having an aromatic ring which comprises a hetero atom.

Preferred values of the substituents A, B, D, L, E, F, G, M, I, J, K, P, Q, S, T, U, V, and W are enumerated below in Table I.


TABLE I

A and B together, form an oxo	A=H B=OAc, L=OH, D=OH, E=H, F=OAc,	A=OCOR B=H, L=D=H; D=H, E-OAc, F=H	A=B=H; E and F together form an oxo, G and M together form an oxo, I=J=O, K=H, P and Q together, form an oxo S and T together, form an oxo U=H V=R, W=R,	G=O M=CH ₂ (epoxide) I=COPh J=H; KP32 OR, P=OCOR Q=OAc, Q=H, S=H T=OR, COR, U=H V=Ar, W=Ar;	A=B=H; E=H F=O (oxetane); G and M together form an oxo, I=COAr J=H; K=OCOR, P=Q=H; S=OCOR T=H, U=Ph V=H,	G=OAc M=CH ₂ O (oxetane); K=OCOAr, S=OR T=H, U=Ar V=H,	G=H M=CH ₂ O (oxetane); S=OH T=H, U=R V=H,	S=H T=OH; U=V=H;
----------------------------------	---	---	---	--	---	--	---	------------------------


Exemplary compounds within the generic formula are depicted hereinbelow:




4



8




5



9

6

-continued



6

7

8

10
5

5

10

15

11

20

25

12

30

35

40

13

45


50

55

14

60

65



15

16

20

25

30

17

35

40

18

45

50

55






19

60

65






9

-continued



10



-continued



In accordance with the process of the present invention, oxazinones 1 are converted to β -amido esters in the presence of an alcohol and an activating agent, preferably a tertiary amine such as triethyl amine, diisopropyl ethyl amine, pyridine, N-methyl imidazole, and 4-dimethylaminopyridine (DMAP). For example, oxazinones 1 react with compounds having the taxane tetracyclic nucleus and a C13 hydroxyl group, in the presence of 4-dimethylaminopyridine (DMAP), to provide substances having a β -amido ester group at C13.



11

Most preferably, the alcohol is 7-O-triethylsilyl baccatin III which can be obtained as described by Greene, et al. in JACS 110, 5917 (1988) or by other routes. As reported in Greene et al., 10-deacetyl baccatin III is converted to 7-O-triethylsilyl baccatin III according to the following reaction scheme:



12




-continued



25

Under what is reported to be carefully optimized conditions, 10-deacetyl baccatin III is reacted with 20 equivalents of $(C_2H_5)_3SiCl$ at $23^\circ C$. under an argon atmosphere for 20 hours in the presence of 50 mL of pyridine/mmole of 10-deacetyl baccatin III to provide 7-triethylsilyl-10-deacetyl baccatin III (31a) as a reaction product in 84–86% yield after purification. The reaction product is then acetylated with 5 equivalents of CH_3COCl and 25 mL of pyridine/mmole of 31a at $0^\circ C$. under an argon atmosphere for 48 hours to provide 86% yield of 7-O-triethylsilyl baccatin III (31b). Greene, et al. in JACS 110, 5917 at 5918 (1988).

As shown in the following reaction scheme, 7-O-triethylsilyl baccatin III 31b may be reacted with an oxazinone 40 to provide a taxol intermediate in which the C-7 and C-2' hydroxyl groups are protected with triethylsilyl and ethoxyethyl protecting groups, respectively. These groups are then hydrolyzed under mild conditions so as not to disturb the ester linkage or the taxol substituents. The synthesis of taxol from oxazinone 2 is carried out as follows:



Although the present scheme is directed to the synthesis of the natural product taxol, it can be used with modifications in either the oxazinone or the tetracyclic alcohol, which can be derived from natural or unnatural sources, to prepare other synthetic taxols contemplated within the present invention.

Alternatively, an oxazinone 1 may be converted to a β -amido ester in the presence of an activating agent and an alcohol other than 7-O-triethylsilyl baccatin III to form a taxol intermediate. Synthesis of taxol may then proceed using the taxol intermediate under an appropriate reaction scheme.

The oxazinone alkyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, hexyl, and the like.

The oxazinone alkenyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.

The oxazinone alkynyl groups, either alone or with the various substituents defined hereinabove are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.

Exemplary oxazinone alkanoyloxy include acetate, propionate, butyrate, valerate, isobutyrate and the like. The more preferred alkanoyloxy is acetate.

The oxazinone aryl moieties described, either alone or with various substituents contain from 6 to 15 carbon atoms and include phenyl, α -naphthyl or β -naphthyl. Substituents include alkanoxy, hydroxy, halogen, alkyl,

13

aryl, alkenyl, acyl, acyloxy, nitro, amino, amido, etc. Phenyl is the more preferred aryl.

As noted above, R_2 and R_5 of oxazinone 1 may be $-OR_8$ with R_8 being alkyl, acyl, ketal, ethoxyethyl ("EE"), 2,2,2-trichloroethoxymethyl, or other hydroxyl protecting group such as acetals and ethers, i.e., methoxy methyl ("MOM"), benzyloxymethyl; esters, such as acetates; carbonates, such as methyl carbonates; and the like. A variety of protecting groups for the hydroxyl group and the synthesis thereof may be found in "Protective Groups in Organic Synthesis" by T. W. Greene, John Wiley and Sons, 1981. The hydroxyl protecting group selected should be easily removed under conditions that are sufficiently mild so as not to disturb the ester linkage or other substituents of the taxol intermediate. However, R_8 is preferably ethoxyethyl or 2,2,2-trichloroethoxymethyl, and most preferably ethoxyethyl.


Preferred values of the oxazinone substituents R_1 , R_2 , R_3 , R_5 , R_6 , R_7 , and R_8 are enumerated herein below:

$R_1 = OR_7$	$R_1 = Ar$	$R_1 = p-MeOPh$	$R_1 = alkyl$	$R_1 = alkenyl$	$R_1 = alkynyl$	$R_1 = H$
$R_2 = OR_8$						
$R_3 = Ph$	$R_3 = Ar$	$R_3 = p-MeOPh$	$R_3 = alkyl$	$R_3 = alkenyl$	$R_3 = alkynyl$	$R_3 = H$
$R_5 = H$						
$R_6 = H$						
$R_7 = alkyl$	$R_7 = alkenyl$	$R_7 = alkynyl$	$R_7 = aryl$	$R_7 = heteroaryl$		
$R_8 = EE$	$R_8 = alkyl$	$R_8 = OCOR$	$R_8 = MOM$	$R_8 = Cl_3CCH_2OCH_2$		


Since the oxazinone 1 has several asymmetric carbons, it is known to those skilled in the art that the compounds of the present invention having asymmetric carbon atoms may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention. More specifically, the present invention includes enantiomers, dia-

14

The oxazinones 1 can be prepared from readily available materials according to the following reaction scheme:



Carboxylic acid 33 may alternatively be prepared according to the method described in Greene et al., JACS 110, 5917 (1988). β -lactams 32 can be prepared from readily available materials, as illustrated in the following reaction scheme in which R_1 and R_3 are phenyl, R_5 and R_6 are hydrogen and R_2 is $-OR_8$ with R_8 being ethoxyethyl:



65 reagents: (a) triethylamine, CH_2Cl_2 , 25° C., 18 h; (b) 4 equiv ceric ammonium nitrate, CH_3CN , -10° C., 10 min; (c) KOH, THF, H_2O , 0° C., 30 min; (d) ethyl vinyl ether, THF, toluene sulfonic acid (cat.), 0° C., 1.5 h; (e)

stereomers, racemic mixtures, and other mixtures thereof.

CH_3Li , ether, -78°C ., 10 min; benzoyl chloride, -78°C ., 1 h.

The starting materials are readily available. α -Acyloxy acetyl chloride is prepared from glycolic acid, and, in the presence of a tertiary amine, it cyclocondenses with imines prepared from aldehydes and p-methoxyaniline to give 1-p-methoxyphenyl-3-acyloxy-4-arylazetidin-2-ones.

The p-methoxyphenyl group can be readily removed through oxidation with ceric ammonium nitrate, and the acyloxy group can be hydrolyzed under standard conditions familiar to those experienced in the art to provide 3-hydroxy-4-arylazetidin-2-ones.

The 3-hydroxyl group may be protected with a variety of standard protecting groups such as the 1-ethoxyethyl group. Preferably, the racemic 3-hydroxy-4-arylazetidin-2-one is resolved into the pure enantiomers prior to protection by recrystallization of the corresponding 2-methoxy-2-(trifluoromethyl) phenylacetic esters and only the dextrorotatory enantiomer is used in the preparation of taxol. In any event, the 3-(1-ethoxyethoxy)-4-phenylazetidin-2-one can be converted to β -lactam 32, by treatment with a base, preferably n-butyllithium, and an aroyl chloride at -78°C . or below.

The following examples illustrate the invention.

EXAMPLE 1

Preparation of

Cis-2,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one 2

cis-1-p-methoxyphenyl-3-acetoxy-4-phenylazetidin-2-one

To a solution of 962 mg (4.56 mmol) of the imine derived from benzaldehyde and p-methoxy aniline, and 0.85 mL (6.07 mmol) of triethylamine in 15 mL of CH_2Cl_2 at -20°C . was added dropwise a solution of 413 mg (3.04 mmol) of α -acetoxy acetyl chloride in 15 mL of CH_2Cl_2 . The reaction mixture was allowed to warm to 25°C . over an 18 h period. The reaction mixture was then diluted with 100 mL of CH_2Cl_2 and the solution was extracted with 30 mL of 10% aqueous HCl. The organic layer was washed with 30 mL of water and 30 mL of saturated aqueous sodium bicarbonate, dried over sodium sulfate, and concentrate to provide a solid mass. The solid was triturated with 50 mL of hexane and the mixture was filtered. The remaining solid was recrystallized from ethyl acetate/hexane to give 645 mg (68%) of cis-1-p-methoxyphenyl-3-acetoxy-4-phenylazetidin-2-one as white crystals, m.p. 163°C .

cis-3-acetoxy-4-phenylazetidin-2-one

To a solution of 20.2 g of cis-1-p-methoxyphenyl-3-acetoxy-4-phenylazetidin-2-one in 700 mL of acetonitrile at -10°C . was slowly added a solution of ceric ammonium nitrate in 450 mL of water over a 1 h period. The mixture was stirred for 30 min at -10°C . and diluted with 500 mL of ether. The aqueous layer was extracted with two 100 mL portions of ether, and the combined organic layer was washed with two 100 mL portions of water, two 100 mL portions of saturated aqueous sodium bisulfite, two 100 mL portions of saturated aqueous sodium bicarbonate and concentrated to give 18.5 g of a solid. Recrystallization of the solid from acetone/hexane gave 12.3 g (92%) of cis-3-acetoxy-4-phenylazetidin-2-one as white crystals, m.p. 152°C .

cis-3-hydroxy-4-phenylazetidin-2-one

To a mixture of 200 mL of THF and 280 mL of 1M aqueous potassium hydroxide solution at 0°C . was added a solution of 4.59 g (22.4 mmol) of cis-3-acetoxy-4-phenylazetidin-2-one in 265 mL of THF via a dropping funnel over a 40 min period. The solution was stirred at 0°C . for 1 h and 100 mL of water and 100 mL of saturated sodium bicarbonate were added. The mixture was extracted with four 200 mL portions of ethyl acetate and the combined organic layers were dried over sodium sulfate and concentrated to give 3.54 g (97%) of racemic cis-3-hydroxy-4-phenylazetidin-2-one as white crystals, m.p. 147°C – 149°C . This material was resolved into its enantiomers by recrystallization of its 2-methoxy-2-(trifluoromethyl)phenylacetic ester from hexane/acetone followed by hydrolysis $[\alpha]^{25}_{\text{H}_2\text{O}} 177^\circ$.

To a solution of 3.41 g (20.9 mmol) of cis-3-hydroxy-4-phenylazetidin-2-one in 15 mL of THF at 0°C . was added 5 mL of ethyl vinyl ether and 20 mg (0.2 mmol) of methane-sulfonic acid. The mixture was stirred at 0°C . for 20 min, diluted with 20 mL of saturated aqueous sodium bicarbonate, and extracted with three 40 mL portions of ethyl acetate. The combined ethyl acetate layers were dried over sodium sulfate and concentrate to give 4.87 g (99%) of cis-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one as a colorless oil.

cis-1-benzoyl-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one

To a solution of 2.35 g (10 mmol) of cis-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one in 40 mL of THF at -78°C . was added 6.1 mL (10.07 mmol) of a 1.65M solution of n-butyllithium in hexane. The mixture was stirred for 10 min at -78°C . and a solution of 1.42 g (10.1 mmol) of benzoyl chloride in 10 mL of THF was added. The mixture was stirred at -78°C . for 1 h and diluted with 70 mL of saturated aqueous sodium bicarbonate and extracted with three 50 mL portions of ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulfate and concentrate to give 3.45 g of an oil. Chromatography of the oil on silica gel eluted with ethyl acetate/hexane gave 3.22 g (95%) of cis-1-benzoyl-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one as a colorless oil.

2R,3S-N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine

To a solution of 460 mg (1.36 mmol) of cis-1-benzoyl-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one in 20 mL of THF at 0°C . was added 13.5 mL of a 1M aqueous solution (13.5 mmol) of potassium hydroxide. The mixture was stirred at 0°C . for 10 min and the THF was evaporated. The mixture was partitioned between 12 mL of a 1N aqueous HCl solution and 30 mL of chloroform. The aqueous layer was extracted with two additional 30 mL portions of chloroform. The combined chloroform extracts were dried over sodium sulfate and concentrated to provide 416 mg (86%) of 2R,3S-N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine (formula 33 in which R_1 and R_3 are phenyl and R_2 is ethoxyethyl).

cis-2,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one 2

To a solution of 416 mg (1.16 mmol) of 2R,3S-N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine in 20 mL of THF was added 261 mg (2.33 mmol) of solid potassium tert-butoxide and the mixture was stirred at 25°C . for 30 min. A solution of 134 mg (1.16 mmol) of methanesulfonyl chloride in 3.2 mL of THF was added and the mixture was stirred at 25°C . for 1.5 h. The mixture was diluted with 80 mL of hexane and ethyl acetate and

this solution was extracted with 20 mL of saturated aqueous sodium bicarbonate solution and 10 mL of brine. The organic phase was dried over sodium sulfate and concentrated to give 256 mg (65%) of cis-2,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one 2 as a colorless oil, $[\alpha]^{25}_{\text{H}_2\text{O}} -22^\circ$ (CHCl_3 , c 1.55).

EXAMPLE 2




Preparation of Taxol

To a small reaction vessel was added 77 mg (0.218 mmol) of (–)-cis-2,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one 2, 40 mg (0.057 mmol) of 7-O-triethylsilyl baccatin III, 6.9 mg (0.057 mmol) of 4-dimethylamino pyridine (DMAP), and 0.029 mL of pyridine. The mixture was stirred at 25° C. for 12 h and diluted with 100 mL of ethyl acetate. The ethyl acetate solution was extracted with 20 mL of 10% aqueous copper sulfate solution, dried over sodium sulfate and concentrated. The residue was filtered through a plug of silica gel eluted with ethyl acetate. Flash chromatography on silica gel eluted with ethyl acetate/hexane followed by recrystallization from ethyl acetate/hexane gave 46 mg (77%) of 2'-O-(1-ethoxyethyl)-7-O-triethylsilyl taxol as a ca. 2:1 mixture of diastereomers and 9.3 mg (23%) of 7-O-triethylsilyl baccatin III. The yield based on consumed 7-O-triethylsilyl baccatin III was quantitative.

A 5 mg sample of 2'-(1-ethoxyethyl)-7-O-triethylsilyl taxol was dissolved in 2 mL of ethanol and 0.5 mL of 0.5% aqueous HCl solution was added. The mixture was stirred at 0° C. for 30 h and diluted with 50 mL of ethyl acetate. The solution was extracted with 20 mL of saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate/hexane to provide 3.8 mg (ca. 90%) of taxol, which was identical with an authentic sample in all respects.

EXAMPLE 3

Preparation of N-Debenzoyl-N-Tertbutoxycarbonyl Taxol



2-tert-butoxy-4-phenyl-4-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one

To a solution of 409 mg (1.16 mmol) of N-tert-butoxycarbonyl-O-(1-ethoxyethyl)-3-phenylisoserine (3) in 20 mL of THF is added 261 mg (2.33 mmol) of solid potassium tert-butoxide and the mixture is stirred at 25° C. for 30 min. A solution of 134 mg (1.16 mmol) of methanesulfonyl chloride in 3.2 mL of THF is added and the mixture is stirred at 25° C. for 1.5 hour. The mixture is diluted with 80 mL of hexane an ethyl acetate and this solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution and 10 mL of brine. The organic phase is dried over sodium sulfate and concentrated to give 235 mg (70%) of 2-tert-butoxy-4-phenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one as a colorless oil.



N-debenzoyl-N-tert-butoxycarbonyl taxol

To a small reaction vessel is added 73 mg (0.218 mmol) of 2-tert-butoxy-4-phenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one, 40 mg (0.057 mmol) of 7-O-triethylsilyl baccatin III, 6.9 mg (0.057 mmol) of 4-dimethylamino pyridine (DMAP), and 0.029 mL of pyridine. The mixture is stirred at 25° C. for 12 hours and diluted with 100 mL of ethyl acetate. The ethyl acetate solution is extracted with 20 mL of 10% aqueous copper sulfate solution, dried over sodium sulfate and concentrated. The residue is filtered through a plug of silica gel eluted with ethyl acetate. Flash chromatography on silica gel eluted with ethyl acetate/hexane followed by recrystallization from ethyl acetate/hexane gives 44 mg (73%) of N-debenzoyl-N-tert-butoxycarbonyl-2'-(1-ethoxyethoxy)-7-O-triethylsilyl taxol as a ca. 1:1 mixture of diastereomers and 9.3 mg (23% of 7-O-triethylsilyl baccatin III).

A 5 mg sample of N-debenzoyl-N-tert-butoxycarbonyl-2'-(2-ethoxyethoxy)-7-O-triethylsilyl taxol is dissolved in 2 mL of ethanol and 0.5 mL of 0.5% aqueous HCl solution is added. The mixture is stirred at 0° C. for 30 hours and diluted with 50 mL of ethyl acetate. The solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue is purified by column chromatography on silica gel eluted with ethyl acetate/hexane to provide 3.8 mg (ca. 90%) of N-debenzoyl-N-tert-butoxycarbonyl taxol.


EXAMPLE 4

Preparation of N-Debenzoyl-N-Tertbutoxycarbonyl-2'-(1-Ethoxyethyl)-3'-Phenyl-Taxol



19

-continued



2-tert-butoxy-4,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one

To a solution of 497 mg (1.16 mmol) of N-tert-butoxycarbonyl-O-(1-ethoxyethyl)-3,3-diphenylisoserine (3) in 20 mL of THF is added 261 mg (2.33 mmol) of solid potassium tert-butoxide and the mixture is stirred at 25° C. for 30 min. A solution of 134 mg (1.16 mmol) of methanesulfonyl chloride in 3.2 mL of THF is added and the mixture is stirred at 25° C. for 1.5 hours. The mixture is diluted with 80 mL of hexane and ethyl acetate, and this solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution and 10 mL of brine. The organic phase is dried over sodium sulfate and concentrated to give 243 mg (59%) of 2-tert-butoxy-4,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one as a colorless oil.


N-debenzoyl-N-tert-butoxycarbonyl-3'-phenyl taxol

To a small reaction vessel is added 90 mg (0.218 mmol) of 2-tert-butoxy-4,4-diphenyl-5-(1-ethoxyethoxy)-4,5-dihydro-1,3-oxazin-6-one, 40 mg (0.057 mmol) of 7-O-triethylsilyl baccatin III, 6.9 mg (0.057 mmol) of 4-dimethylamino pyridine (DMAP), and 0.029 mL of pyridine. The mixture is stirred at 25° C. for 12 hours and diluted with 100 mL of ethyl acetate. The ethyl acetate solution is extracted with 20 mL of 10% aqueous copper sulfate solution, dried over sodium sulfate and concentrated. The residue is filtered through a plug of silica gel eluted with ethyl acetate. Flash chromatograph on silica gel eluted with ethyl acetate/hexane followed by recrystallization from ethyl acetate/hexane gives 44 mg (66%) of N-debenzoyl-N-tert-butoxycarbonyl-2'-(2-ethoxyethyl)-3'-phenyl-7-O-triethylsilyl taxol as a ca. 3:1 mixture of diastereomers.

A 5 mg sample of N-debenzoyl-N-tert-butoxycarbonyl-2'-(2-ethoxyethyl)-3'-phenyl-7-O-triethylsilyl taxol is dissolved in 2 mL of ethanol and 0.5 mL of 0.5% aqueous HCl solution is added. The mixture is stirred at 0° C. for 30 hours and diluted with 50 mL of ethyl acetate. The solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue is purified by column chromatography on silica gel eluted with ethyl acetate/hexane to provide 4.0 mg (ca. 90%) of N-debenzoyl-N-tert-butoxycarbonyl-3'-phenyl taxol.


EXAMPLE 5

Preparation of
2,4-Diphenyl-5-(1-Ethoxyethoxy)-5-Methyl-4,5-Dihydro-1,3-Oxazin-6-One



20

-continued



To a solution of 430 mg (1.16 mmol) of N-benzoyl-O-(1-ethoxyethyl)-2-methyl-3-phenylisoserine in 20 mL of THF is added 261 mg (2.33 mmol) of solid potassium tert-butoxide and the mixture is stirred at 25° C. for 30 min. A solution of 134 mg (1.16 mmol) of methanesulfonyl chloride in 3.2 mL of THF is added and the mixture is stirred at 25° C. for 1.5 hour. The mixture is diluted with 80 mL of hexane and ethyl acetate and this solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution and 10 mL of brine. The organic phase is dried over sodium sulfate and concentrated to give 270 mg (76%) of 2,4-diphenyl-5-(1-ethoxyethoxy)-5-methyl-4,5-dihydro-1,3-oxazin-6-one as a colorless oil.

EXAMPLE 6

3'-Methyl Taxol

To a small reaction vessel is added 77 mg (0.218 mmol) of 2,4-diphenyl-5-(1-ethoxyethoxy)-5-methyl-4,5-dihydro-1,3-oxazin-6-one, 40 mg (0.057 mmol) of 7-O-triethylsilyl baccatin III, 6.9 mg (0.057 mmol) of 4-dimethylamino pyridine (DMAP), and 0.029 mL of pyridine. The mixture is stirred at 25° C. for 12 hours and diluted with 100 mL of ethyl acetate. The ethyl acetate solution is extracted with 20 mL of 10% aqueous copper sulfate solution, dried over sodium sulfate and concentrated. The residue is filtered through a plug of silica gel eluted with ethyl acetate. Flash chromatograph on silica gel eluted with ethyl acetate/hexane followed by recrystallization from ethyl acetate/hexane gives 32 mg (53%) of 2'-(1-ethoxyethyl)-3'-methyl-7-O-triethylsilyl taxol as a ca. 1:1 mixture of diastereomers.

A 5 mg sample of 2'-(1-ethoxyethyl)-3'-methyl-7-O-triethylsilyl taxol is dissolved in 2 mL of ethanol and 0.5 mL of 0.5% aqueous HCl solution is added. The mixture is stirred at 0° C. for 30 hours and diluted with 50 mL of ethyl acetate. The solution is extracted with 20 mL of saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated. The residue is purified by column chromatography on silica gel eluted with ethyl acetate/hexane to provide 3.9 mg (ca. 90%) of 3'-methyl taxol.

In view of the above, it will be seen that the several objects of the invention are achieved.


As various changes could be made in the above compositions and processes without departing from the scope of the invention, it is intended that all matter

21

contained in the above description be interpreted as illustrative and not in a limiting sense.

What is claimed is:

1. An oxazinone of the formula



wherein R₁ is aryl, alkyl, alkenyl, alkynyl or —OR₇, R₃, R₅ and R₆ are independently selected from hydrogen alkyl, alkenyl, alkynyl, and aryl, R₇ is alkyl, alkenyl, alkynyl, or aryl, and R₈ is a hydroxyl protecting group.

2. The compound of claim 1 wherein the hydroxyl protecting group is selected from the group consisting of acetals, ethers, and carbonates.

3. The compound of claim 1 wherein R₁ is —OR₇, R₃ is phenyl, and R₇ and R₈ are as previously defined.


4. The compound of claim 3, wherein R₈ is ethoxyethyl or 2,2,2-trichloroethoxymethyl.

5. The compound of claim 1 wherein aryl is C₆₋₁₅ aryl, alkyl is C₁₋₁₅ alkyl, alkenyl is C₂₋₁₅ alkenyl and alkynyl is C₂₋₁₅ alkynyl.

6. The compound of claim 1 wherein R₁ and R₃ are phenyl, α-naphthyl or β-naphthyl.

7. The compound of claim 1 wherein R₁ is —OR₇ and R₇ is tert-butyl.

8. A process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone having the formula



wherein R₁ is aryl, alkyl, alkenyl, alkynyl or —OR₇ wherein R₇ is alkyl, alkenyl, alkynyl, or aryl; R₂ and R₅ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, and —OR₈ wherein R₈ is alkyl, alkenyl, alkynyl, aryl, or hydroxyl protecting group; and R₃ and R₆ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, and aryl, the contacting of said alcohol and oxazinone being carried out in the presence of a sufficient amount of an activating agent to cause the oxazinone to react with the alcohol to form a β-amido ester which is suitable for use as an intermediate in the synthesis of taxol.


9. The process of claim 8 wherein aryl is C₆₋₁₅ aryl, alkyl is C₁₋₁₅ alkyl, alkenyl is C₂₋₁₅ alkenyl and alkynyl is C₂₋₁₅ alkynyl.

10. The process of claim 8 wherein the hydroxyl protecting group is selected from acetals, ethers, and carbonates.

11. The process of claim 8 wherein R₁ is aryl, R₂ is —OR₈ with R₈ being ethoxyethyl or 2,2,2-trichloroethoxymethyl, and R₃ is aryl.

12. The process of claim 8 wherein the alcohol has the formula:

22



wherein R₄ is a hydroxyl protecting group, Ph is phenyl and Ac is acetyl.

13. The process of claim 12 wherein R₄ is selected from ethers, carbonates and silyl groups.


14. The process of claim 8 wherein the activating agent is a tertiary amine.

15. The process of claim 8 wherein the activating agent is triethyl amine, diisopropyl ethyl amine, pyridine, N-methyl imidazole, or 4-dimethyl-aminopyridine.

16. The process of claim 8 wherein R₁ is —OR₇ and R₇ is tert-butyl.


17. The process of claim 12 wherein R₁ is —OR₇ and R₇ is tert-butyl.

18. An oxazinone of the formula



wherein R₁ is phenyl or substituted phenyl, alkyl, alkenyl, alkynyl or —OR₇, R₃, R₅ and R₆ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, phenyl and substituted phenyl, R₇ is alkyl, alkenyl, alkynyl, or phenyl, and R₈ is a hydroxyl protecting group, and the phenyl substituents are selected from alkanoxy, halogen, alkyl, alkenyl, acyl, acyloxy, nitro, amino or amido.


19. An oxazinone of the formula



wherein R₁ is phenyl or substituted phenyl, alkyl, alkenyl, alkynyl or —OR₇, R₃ is hydrogen, alkyl, alkenyl, alkynyl, or aryl, R₇ is alkyl, alkenyl, alkynyl, or aryl, R₅ and R₆ are hydrogen, and R₈ is a hydroxyl protecting group and the phenyl substituents are selected from alkanoxy, halogen, alkyl, alkenyl, acyl, acyloxy, nitro, amino or amido.

20. The oxazinone of claim 19 wherein R₁ is phenyl or substituted phenyl or —OR₇ and R₇ is alkyl.

21. An oxazinone of the formula




23

wherein R_1 is aryl, alkyl, alkenyl, alkynyl or $-\text{OR}_7$, R_3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl, R_7 is alkyl, R_5 and R_6 are hydrogen, and R_8 is a hydroxyl protecting group.

22. The oxazinone of claim 21 wherein R_1 is aryl or $-\text{OR}_7$ and R_7 is alkyl.

23. A process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone having the formula



wherein R_1 is aryl, alkyl, alkenyl, alkynyl or $-\text{OR}_7$, R_3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl, R_7 is alkyl, alkenyl, alkynyl, or aryl, R_5 and R_6 are hydrogen, and R_8 is a hydroxyl protecting group,


the contacting of said alcohol and oxazinone being carried out in the presence of a sufficient amount of an activating agent to cause the oxazinone to react

24

with the alcohol to form a β -amido ester which is suitable for use as an intermediate in the synthesis of taxol.

24. The process of claim 23 wherein R_1 is aryl or $-\text{OR}_7$ and R_7 is alkyl.

25. A process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone having the formula



wherein R_1 is aryl, alkyl, or $-\text{OR}_7$, R_3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl, R_7 is alkyl, alkenyl, alkynyl, or aryl, R_5 and R_6 are hydrogen, and R_8 is a hydroxyl protecting group.

26. The process of claim 25 wherein R_1 is aryl or $-\text{OR}_7$ and R_7 is alkyl.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 5,384,399
DATED : January 24, 1995
INVENTOR(S) : Robert A. Holton

Page 1 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 4, lines 1-11, the chemical structure (3) should read:

(3)



In column 5, line 33, the portion of Table 1 that reads "K=H, K=OH, KP32 OR," should read -- K=H, K=OH, K=OR, --.

In column 5, line 37, the portion of Table 1 that reads:

"form an oxo T-O- T=OR, T=H, T=H, T=H, T=OH;
OCOR"

should read

--form an oxo T-O-OCOR T=OR, T=H, T=H, T=H, T=OH; --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,384,399

Page 2 of 10


DATED : January 24, 1995

INVENTOR(S) : Robert A. Holton

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 5, lines 46-56, the chemical structure (4) should read:

(4)



In column 6, lines 2-12, the chemical structure (6) should read:

(6)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,384,399

Page 3 of 10


DATED : January 24, 1995

INVENTOR(S) : Robert A. Holton

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 6, lines 45-56, the chemical structure (8) should read:

(8)



In column 7, lines 3-13, the chemical structure (10) should read:

(10)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,384,399

Page 4 of 10


DATED : January 24, 1995

INVENTOR(S) : Robert A. Holton

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 7, lines 30-40, the chemical structure (12) should read:

(12)



In column 7, lines 57-67, the chemical structure (14) should read:

(14)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,384,399

Page 5 of 10


DATED : January 24, 1995

INVENTOR(S) : Robert A. Holton

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 8, lines 16-26, the chemical structure (16) should read:

(16)



In column 8, lines 43-53, the chemical structure (18) should read:

(18)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 5,384,399
DATED : January 24, 1995
INVENTOR(S) : Robert A. Holton

Page 6 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 9, lines 4-14, the chemical structure (20)
should read:

(20)



In column 9, lines 30-40, the chemical structure (22)
should read:

(22)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 5,384,399
DATED : January 24, 1995
INVENTOR(S) : Robert A. Holton

Page 7 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 9, lines 57-67, the chemical structure (24)
should read:

(24)



In column 10, lines 13-23, the chemical structure (26)
should read:

(26)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 5,384,399
DATED : January 24, 1995
INVENTOR(S) : Robert A. Holton

Page 8 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In column 10, lines 25-35, the chemical structure (27)
should read:

(27)



In column 10, lines 37-47, the chemical structure (28)
should read:

(28)



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 5,384,399
DATED : January 24, 1995
INVENTOR(S) : Robert A. Holton

Page 9 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 10, lines 48-58, the chemical structure (29) should read:


(29)



In column 11, line 12, the portion of the chemical structure reading "1. (C₂H₅)₃SiCl, C₅H₅H" should read -- 1. (C₂H₅)₃SiCl, C₅H₅N --.

In column 13, line 24, the portion of the table reading "R₃ = H" should read -- R₃ = H --.

In column 19, lines 65-68, the chemical structure should read:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,384,399

Page 10 of 10

DATED : January 24, 1995

INVENTOR(S) : Robert A. Holton

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 21, claim 4, line 23, "claim 3," should read
-- claim 3 --.

Signed and Sealed this

Thirteenth Day of January, 1998



Attest:

BRUCE LEHMAN

Attesting Officer

Commissioner of Patents and Trademarks